期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 73, 期 2, 页码 190-209出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.09.089
关键词
cardiovascular; EndMT; endothelial to mesenchymal transition
资金
- British Heart Foundation [RG/14/3/30706] Funding Source: Medline
- NHLBI NIH HHS [R01 HL114805, R01 HL141917, R01 HL136431, R01 HL130423] Funding Source: Medline
- British Heart Foundation [RG/14/3/30706] Funding Source: researchfish
Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis. Therefore, the targeting of EndMT may hold therapeutic promise for treating CVD. However, the field faces a number of challenges, including the lack of a precise functional and molecular definition, a lack of understanding of the causative pathological role of EndMT in CVDs (versus being a bystander-phenomenon), and a lack of robust human data corroborating the extent and causality of EndMT in adult CVDs. Here, we review this emerging but exciting field, and propose a framework for its systematic advancement at the molecular and translational levels. (J Am Coll Cardiol 2019; 73: 190-209) (c) 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据